Toxic optic neuropathies.
Altiparmak UE.
Curr Opin Ophthalmol. 2013 Nov;24(6):534-9. doi: 10.1097/ICU.0000000000000001.
Preservation of vision after CaMKII-mediated protection of retinal ganglion cells.
Guo X, Zhou J, Starr C, Mohns EJ, Li Y, Chen EP, Yoon Y, Kellner CP, Tanaka K, Wang H, Liu W, Pasquale LR, Demb JB, Crair MC, Chen B.
Cell. 2021 Aug 5;184(16):4299-4314.e12. doi: 10.1016/j.cell.2021.06.031. Epub 2021 Jul 22.
Rotenone-Induced Optic Nerve Damage and Retinal Ganglion Cell Loss in Rats.
Yamamoto Y, Taniguchi T, Shimazaki A.
Biomolecules. 2024 Aug 23;14(9):1047. doi: 10.3390/biom14091047.
Toxic optic neuropathies: an updated review.
Grzybowski A, Zülsdorff M, Wilhelm H, Tonagel F.
Acta Ophthalmol. 2015 Aug;93(5):402-410. doi: 10.1111/aos.12515. Epub 2014 Aug 27.
New tools for studying microglia in the mouse and human CNS.
Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, Weissman IL, Chang EF, Li G, Grant GA, Hayden Gephart MG, Barres BA.
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1738-46. doi: 10.1073/pnas.1525528113. Epub 2016 Feb 16.
Lesions of the optic nerve.
Atkins EJ, Newman NJ, Biousse V.
Handb Clin Neurol. 2011;102:159-84. doi: 10.1016/B978-0-444-52903-9.00012-1.
Linezolid-Induced Toxic Optic Neuropathy.
Aljebreen MA, Alotaibi AK, Alrobaian M.
Middle East Afr J Ophthalmol. 2021 Jan 19;27(4):235-237. doi: 10.4103/meajo.MEAJO_73_20. eCollection 2020 Oct-Dec.
Drug-Induced Retinal Toxicity.
Tsang SH, Sharma T.
Adv Exp Med Biol. 2018;1085:227-232. doi: 10.1007/978-3-319-95046-4_48.
The effect of idebenone and corticosteroid treatment on methanol-induced toxic optic nerve and retinal damage in rats: biochemical and histopathological examination.
Nalcacioglu P, Kavuncu S, Taskin Turkmenoglu T, Sonmez CA.
Cutan Ocul Toxicol. 2022 Sep;41(3):250-256. doi: 10.1080/15569527.2022.2106994. Epub 2022 Aug 5.
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).
Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.
